Amendment to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing Of The Claims:

Claim 1 (Currently amended): A method for reducing symptoms of ~~an~~ a complement-activation related immediate hypersensitivity reaction due to the presence of ~~an~~ amphiphilic carrier comprising administering a composition comprising a hypersensitivity reducing amount of a complement activation inhibitor, a therapeutic amount of an active ingredient(s) and an amphiphilic carrier to a subject ~~having a condition responsive to the active ingredient(s)~~, wherein said amphiphilic carrier is polyethoxylated oil ~~or a derivatized polyethoxylated oil and is~~ capable of causing an immediate hypersensitivity reaction in the subject, ~~and wherein the active ingredient is taxol, paclitaxel, Doxil, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide, doxorubicin, daunorubicin, amphoterin B, hemoglobin, polynucleotide or a multivitamin~~ and wherein the complement activation inhibitor is selected from complement receptor type 1 derived protein(s) ~~sCR1~~, GS1, Factor H, Factor I, C1Inh ~~C1qInh~~, complstatin ~~complestatin~~, ~~and~~ anti-C5a, compound K-76COOH, ~~synthetic peptide analogues of the C terminal part of C3, indel proximal peptides, serine esterase inhibitors,~~ or antibodies specific for complement ~~and anti-lipid antibodies~~.

Claim 2 (Currently amended): The method according to claim 1 wherein said composition further comprises a pharmaceutical solvent, ~~and~~ emulsifiers or detergent.

Claim 3 (Currently amended): The method according to claim 2 wherein the pharmaceutical solvent is a hydrophilic or hydrophobic carrier vehicle ~~solvent~~.

Claim 4 (Previously presented): The method according to claim 1 wherein the polyethoxylated oil is polyethoxylated castor oil.

Claims 5-9 (Cancelled)

Claim 10 (Previously presented): The method of claim 1 wherein the administration includes: administering to said individual the complement activation inhibitor prior to the administration of said active ingredient.

Claim 11-15 (Canceled)

Claim 16 (Previously presented): The method according to claim 1 wherein said active ingredient is doxorubicin, daunorubicin or amphotericin B.

Claim 17 (Previously presented): The method according to claim 1 wherein the active ingredient is hemoglobin or polynucleotides.

Claims 18-20 (Cancelled)

Claim 21 (Currently amended): The method according to claim 1 wherein the complement activation inhibitor is sCR1[[,]] or GS1~~, and anti-lipid antibodies~~.

Claim 22 (Cancelled)

Claim 23 (New) The method according to claim 1 wherein the active agent is paclitaxel, Doxil, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide, doxorubicin, daunorubicin, amphoterin B, hemoglobin, polynucleotide or multivitamin.